Sector ratings Arrowhead Pharmaceuticals, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 08/12/2025 GMT			5-day change	1st Jan Change
68.60 ^USD	+11.65%		+21.96%	+264.89%

12-02	Arrowhead Pharmaceuticals Gets FDA Breakthrough Tag for Triglyceride Drug	MT
12-02	Arrowhead Pharmaceuticals receives FDA breakthrough therapy designation for plozasiran	RE

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
ARROWHEAD PHARMACEUTICALS, INC.	9.32B	-	BBB	-		-
ARGENX SE	55.71B		AA
INSMED INCORPORATED	41.92B	-	BBB	-		-
WUXI APPTEC CO., LTD.	38.56B		AAA
BIONTECH SE	23.39B	-	-	-		-
GENMAB A/S	19.7B		AA
WUXI BIOLOGICS (CAYMAN) INC.	17.43B		AAA
AKESO, INC.	14.73B		B			-
SUMMIT THERAPEUTICS INC.	14.36B	-	-	-		-
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	13.36B	-	A	-		-
MADRIGAL PHARMACEUTICALS, INC.	12.91B	-	B	-		-
EXELIXIS, INC.	11.35B		BB
TRANSTHERA SCIENCES (NANJING), INC.	9.59B	-	-	-	-	-	-	-
SAMSUNG EPIS HOLDINGS CO., LTD.	8.73B	-	-	-	-	-	-	-
NUVALENT, INC.	8.38B	-	CCC	-		-
CEREVEL THERAPEUTICS HOLDINGS, INC.	8.19B	-	-	-	-	-	-	-
CYTOKINETICS, INCORPORATED	7.84B	-	AA	-		-
METSERA, INC.	7.43B	-	B	-	-	-	-
MERUS N.V.	7.3B	-	BBB	-		-
ABL BIO INC.	7.01B	-	CCC	-		-
Average	16.86B		A
Weighted average by Cap.			A